Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era
Introduction: We have conducted molecular profiling through high-throughput molecular test as part of clinical practice for patients with advanced gastrointestinal (GI) cancer, or rare cancer including gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Aim(s): Herein, we reported the molecular characterization for 15 metastatic GEP-NET patients.
Materials and methods: We conducted the Ion AmpliSeq Cancer Hotspot Panel v2 (detecting 2,855 oncogenic mutations in 50 commonly mutated genes) and nCounter Copy Number Variation Assay (designed a 21-genes based on available targeted agents) as high throughput genomic platform in 14 patients with metastatic GEP-NETs.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Park Y
To read the full abstract, please log into your ENETS Member account.